Table 1.
Patient characteristics
| N = 27 (%) | |
|---|---|
| General characteristics | |
| Median age in years | 60 (47–76)& |
| Median body weight in kg | 70.4 (46.4–105)& |
| Gender | |
| Female | 15 (55.6) |
| Male | 12 (44.4) |
| Race | |
| African | 4 (14.8) |
| Asian | 3 (11.1) |
| Caucasian | 20 (74.1) |
| Tumor type | |
| Non–small cell lung cancer | 4 (14.8) |
| Small cell cancer | 3 (11.1) |
| Pancreatic adenocarcinoma | 3 (11.1) |
| Cholangiocarcinoma | 3 (11.1) |
| Ovarian/fallopian tube cancer | 3 (11.1) |
| Prostate cancer (mCRPC)$ | 3 (11.1) |
| Cervical cancer | 2 (7.4) |
| Colorectal cancer | 2 (7.4) |
| Mesothelioma | 2 (7.4) |
| Myxofibrosarcoma | 1 (3.7) |
| Thymic cancer | 1 (3.7) |
| Renal function | |
| Mild renal impairment (eGFR = 60–90 ml/min/1.73 m2) | 13 (48.1) |
| Normal renal function (eGFR > 90 ml/min/1.73 m2) | 14 (51.9) |
| Presence of proteinuria | 5 (18.5) |
| NCT02769962 (NLG207 + olaparib) | |
| Total | 24 (88.9) |
| Cycle 1 PK collection Only | 19 (79.9)# |
| Cycle 1 + Cycle 6 PK collection | 5 (20.1)# |
| NCT03531827 (NLG207 + enzalutamide) | |
| Total | 3 (11.1) |
| Cycle 1 PK collection Only | 3 (100)# |
eGFR estimated glomerular filtration rate
&Range of data reported
$All three prostate cancer patients were enrolled on NCT03531827
#Percentage of subgroup data within the selected population